Bioanalytical Systems

Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

The full company name is Basis Global Technologies Inc - Ordinary Shares - Class A.

WEST LAFAYETTE, Ind., March 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced a change of the Company's corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc.

Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.

Inmode Ltd

Semler Scientific

MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.

Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy

WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced plans to expand the Company's service offerings to add cardiovascular safety pharmacology capabilities to the existing capabilities for respiratory and central nervous system safety pharmacology.

Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology

WEST LAFAYETTE, Ind., March 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services continues to invest in expanding services and adding capacity to meet client needs and growth expectations. In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium. Last month, the additional West Lafayette capacity was successfully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. The Company believes this is an important step forward as it remains focused on strategic growth.

Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN

WEST LAFAYETTE, Ind., March 04, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that Robert Leasure, Jr., President and Chief Executive Officer, and Beth Taylor, Vice President of Finance and Chief Financial Officer, are scheduled to participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. Management will be available for one-on-one meetings throughout both days. A webcast of the presentation will be available on March 9, 2021, at 7:00 a.m. ET through a link that will be posted on the Investors section of the Company's website at  ir.inotivco.com  and will be available for approximately 90 days.

Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference

WEST LAFAYETTE, Ind., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced additional investments in laboratory infrastructure and data and study management technologies in order to support the Company's growth strategy and service delivery goals for clients.

Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Laboratory Infrastructure and Data and Study Management Technologies

WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021.

Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer

Bioanalytical Systems, Inc. (BASI) CEO Bob Leasure on Q1 2021 Results - Earnings Call Transcript

WEST LAFAYETTE, Ind., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced financial results for the three months ended December 31, 2020 (“Q1 FY 2021”).

Bioanalytical Systems, Inc., Announces First Quarter Fiscal 2021 Financial Results

WEST LAFAYETTE, Ind., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that the Company will issue its financial results press release for the fiscal 2021 first quarter ended December 31, 2020, on Tuesday, February 9, 2021, after the close of the stock market, and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.

Bioanalytical Systems, Inc., to Report First Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, February 9, 2021

WEST LAFAYETTE, Ind., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the most recent hiring related to the continued expansion of the Company's pathology service offerings through ongoing investment and key hires. Effective January 18, 2021, Adam Aulbach, DVM, DACVP, joined the Company as Director, Clinical Pathology.

Inotiv Broadens Pathology Service Offerings

WEST LAFAYETTE, Ind., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that Daniel Smeak, DVM, ACVS, has joined the Company as Vice President, Surgical Models, effective December 30, 2020.

Daniel Smeak, DVM, ACVS, Joins Inotiv as Vice President, Surgical Models

WEST LAFAYETTE, Ind., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced financial results for the three and twelve months ended September 30, 2020.

BASi Releases Earnings for Fourth Quarter of Fiscal 2020

WEST LAFAYETTE, Ind., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that it will report financial results for the three and twelve months ended September 30, 2020, prior to market opening on Monday, December 21, 2020. If there are any questions after the press release is issued, please direct your comments to the investor relations contact noted in this release.

BASi to Release Earnings for Fourth Quarter of Fiscal 2020 on Monday, December 21, 2020

WEST LAFAYETTE, Ind., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of drug discovery and development services, announced today that Andrew N. Alexander, DVM, Ph.D., MBA, DABT, has joined the Company as Vice President, Pharmacology and Toxicology Operations, effective October 19, 2020.

Andrew N. Alexander, DVM, Ph.D., MBA, DABT, Joins Inotiv as Vice President, Pharmacology and Toxicology Operations

WEST LAFAYETTE, Ind., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that it will participate in the H.C. Wainright 22nd Annual Global Investment Conference. The Company will present on Wednesday, September 16th, at 2:30 p.m. EDT.

BASi to Participate in H.C. Wainright Investment Conference

WEST LAFAYETTE, Ind., Aug.  14, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced financial results for the three months ended June 30, 2020.

BASi Releases Earnings for Third Quarter of Fiscal 2020

WEST LAFAYETTE, Ind., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, announced today that I.M. (Gina) Grossi, Ph.D., has joined the Company as Vice President, Toxicology, effective August 10, 2020. Dr. Grossi joins as the Company continues to invest in people and facilities to support the growing demand for Inotiv services.

I.M. (Gina) Grossi, Ph.D., Joins Inotiv as Vice President of Toxicology to Drive Growth of Expanding Toxicology Business

WEST LAFAYETTE, Ind., May  14, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced financial results for the three months ended March 31, 2020.

BASi Releases Earnings for Second Quarter of Fiscal 2020

WEST LAFAYETTE, Ind., May  05, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, is pleased to announce the addition of Diane Tutko Francisco, Ph.D., as Sr. Director, Client Experience, effective April 30, 2020.

Diane Tutko Francisco, Ph.D., Joins Inotiv to Lead Client Experience Team

WEST LAFAYETTE, Ind., April  24, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the closing and receipt of funds from the  SBA Paycheck Protection Program  (“PPP”).

BASi Announces Borrowing under Paycheck Protection Program

WEST LAFAYETTE, Ind., March  09, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ: BASI), operating as Inotiv (the “Company” or “Inotiv”), today announced the appointment of Beth A. Taylor, CPA, as Vice President - Finance and Chief Financial Officer of the Company. Ms. Taylor succeeds Jill C. Blumhoff, who had served as the Company’s Vice President - Finance and Chief Financial Officer since May 2016.

Bioanalytical Systems, Inc. d/b/a Inotiv Appoints Beth A.

WEST LAFAYETTE, Ind., Feb.  12, 2020  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ: BASI), operating as Inotiv (the “Company” or “Inotiv”), is pleased to announce the launch of its new website,  inotivco.com . The website reinforces the Company’s new brand, “Inotiv,” which symbolizes the union of legacy contract research services with those acquired in the Seventh Wave Laboratories, Smithers Toxicology Services, and Pre-Clinical Research Services acquistions. Inotiv provides top-tier in vivo toxicology, pharmacology, drug metabolism, bioanalysis, pharmacokinetic, and surgical and medical device discovery and development solutions.

Inotiv Launches Website for Newly Unified Contract Research Services

WEST LAFAYETTE, Ind., Dec.  03, 2019  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, announced today the closing of the  previously announced agreement  to purchase substantially all of the assets of Pre-Clinical Research Services, Inc. (“PCRS”), a premier provider of surgical and medical device contract research services. In connection with the closing, the Company also closed on additional funding, which positions the Company to make future investments in organic growth in the drug metabolism and pharmacokinetics arena.

Inotiv, a BASi Company, Announces Closing of Pre-Clinical Research Services Transaction, Including New Financing to Fund the Transaction and Expand Discovery and DMPK Business

WEST LAFAYETTE, Ind., Nov.  14, 2019  (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”), is pleased to announce the launch of its new contract research services brand, Inotiv. Inotiv represents the union of Bioanalytical Systems, Inc.’s (BASi’s), Seventh Wave Laboratories’, and Smithers Avanza Toxicology Services’ in vivo toxicology, pharmacology, drug metabolism, bioanalysis, and pharmacokinetic (PK) solutions, as well as the Company’s expansion into surgical and medical device contract research services with the expected acquisition of the Pre-Clinical Research Services business. The rebrand reflects the Company’s increased scope of services and its resulting position as a top contract research organization (CRO) for drug discovery and development.  

News for Bioanalytical Systems Stock (BASI)